Biochemical markers of bone turnover

被引：10
作者：
Carey J.J. [1 ,2 ,4 ]
Licata A.A. [2 ,3 ]
Delaney M.F. [1 ,2 ]
机构：
[1] Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH
[2] Center for Osteoporosis and Metabolic Bone Disease, Cleveland Clinic Foundation, Cleveland, OH
[3] Department of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
[4] Department of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH 44120
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2006年 / 4卷 / 3期
关键词：
Biochemical markers of bone turnover; Least significant change; Osteoporosis; Paget's disease of bone;
D O I：
10.1385/BMM:4:3:197
中图分类号：
学科分类号：
摘要：
Recent developments in biomarkers in many fields of medicine have expanded the array of tools health care providers can use today for disease management. Essentially, biomarkers assist clinicians today in four main ways: screening, diagnosis, assessment of severity or risk, and monitoring of, or deciding on, treatment (1). Surrogate markers known as biochemical markers of bone turnover have been used for decades in the management of diseases of the skeleton. Historically, bone biomarkers required 24-h urine collections, lacked accuracy and reliability, and were cumbersome to use. More recently, they have been shown to be effective surrogates for assessments of treatment response and efficacy in osteoporosis. Although used extensively in research and development and in metabolic bone disease clinics, they are still infrequently used tools for osteoporosis management in clinical practice. Today they have been incorporated into the assessment and management of a variety of diseases of bone including complex metabolic bone disorders, osteoporosis, Paget's disease of bone, and skeletal metastases. Developments in the last decade have greatly enhanced their performance characteristics. A variety of tests and assays are now widely available and significantly more accurate and reliable measures of bone metabolism have been developed. However, techniques and assays vary substantially. In order to maximize their clinical usefulness, an understanding of their strengths and weaknesses, factors that influence them, and knowledge of their unique intricacies is crucial for the ordering physician during the decision- making process. As the field continues to develop, more specific markers and standardization of measurement techniques will enhance reliability, which facilitate their use in practice. The aim of this review is to increase knowledge of the variety of tests available, their potential and limitations, and current best practice for practitioners and researchers, focusing primarily on their use in the management of osteoporosis. © Copyright 2006 by Humana Press Inc. All rights of any nature whatsoever reserved.
引用
收藏
页码：197 / 211
页数：14
相关论文
共 114 条
[21]  
Franke S., Lehmann G., Abendroth K., Hein G., Stein G., PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure, Eur J Med Res, 3, pp. 81-88, (1998)
[22]  
Montagnani A., Gonnelli S., Cepollaro C., Et al., Anew serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy, Eur J Intern Med, 14, pp. 172-177, (2003)
[23]  
Rosen H.N., Moses A.C., Garber J., Et al., Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy, Calcif Tissue Int, 66, pp. 100-103, (2000)
[24]  
Rosen C.J., Hochberg M.C., Bonnick S.L., Et al., Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study, J Bone Miner Res, 20, pp. 141-151, (2005)
[25]  
Miller P.D., McClung M.R., Macovei L., Et al., Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study, J Bone Miner Res, 20, pp. 1315-1322, (2005)
[26]  
Greenspan S.L., Resnick N.M., Parker R.A., Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial, J Clin Endocrinol Metab, 90, pp. 2762-2767, (2005)
[27]  
Valimaki M.J., Tahtela R., Serum tartrate-resistant acid phosphatase 5b or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate therapy in postmenopausal osteoporosis?, Clin Chem, 51, pp. 2382-2385, (2005)
[28]  
Tahtela R., Seppanen J., Laitinen K., Katajamaki A., Risteli J., Valimaki M.J., Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: A comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen aminoterminal propeptide, Osteoporos Int, 16, pp. 1109-1116, (2005)
[29]  
Gundberg C.M., Looker A.C., Nieman S.D., Calvo M.S., Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity, Bone, 31, pp. 703-708, (2002)
[30]  
Greenspan S.L., Emkey R.D., Bone H.G., Et al., Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 137, pp. 875-883, (2002)
12345678910